This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
BioPharma Drive: Drug Pricing
SEPTEMBER 25, 2024
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
BioPharma Drive: Drug Pricing
MAY 21, 2024
Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.
111 
BioPharma Drive: Drug Pricing
DECEMBER 12, 2023
Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”
119 
BioPharma Drive: Drug Pricing
AUGUST 22, 2023
Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.
98 
BioPharma Drive: Drug Pricing
APRIL 22, 2024
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
BioPharma Drive: Drug Pricing
MARCH 1, 2024
Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.
119 
BioPharma Drive: Drug Pricing
MARCH 1, 2024
The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.
BioPharma Drive: Drug Pricing
SEPTEMBER 7, 2023
The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.
BioPharma Drive: Drug Pricing
JUNE 18, 2024
Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.
BioPharma Drive: Drug Pricing
JULY 11, 2023
RA Capital led a Series B financing round that drew participation from more than a dozen blue-chip venture backers, including new investors Goldman Sachs and Vertex Ventures.
Vial
MAY 20, 2024
Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. What is a Pre-Clinical CRO? The global preclinical CRO market was estimated to be valued at US$5.7
BioPharma Drive: Drug Pricing
OCTOBER 22, 2024
A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
64 
BioPharma Drive: Drug Pricing
JANUARY 12, 2024
Arena BioWorks, which will be led by Harvard University scientist Stuart Schreiber, seeks to blend academic and venture capital drug research models.
128 
BioPharma Drive: Drug Pricing
DECEMBER 7, 2023
The funding is indicative of investor interest in an area of drug research that involves at least a dozen startups and multiple publicly traded companies.
131 
Drugs.com
OCTOBER 24, 2023
23, 2023 -- New research suggests a link between middle school students being disciplined for marijuana use and legalization of recreational weed, particularly when schools are close to dispensaries that sell the drug. Researchers. MONDAY, Oct.
110 
BioPharma Drive: Drug Pricing
DECEMBER 13, 2023
The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.
114 
BioPharma Drive: Drug Pricing
AUGUST 16, 2024
Some industry watchers described the level of price discounts announced by Medicare as a "relief," though they warned of bigger future implications for drug research.
70 
Chemical Biology and Drug Design
JULY 5, 2024
Abstract Intestinal absorption of compounds is significant in drug research and development. The QSPR model accurately predicted the intestinal absorption of molecules, and the computer simulation found the mechanism of molecular structure affecting intestinal absorption.
100 
BioPharma Drive: Drug Pricing
AUGUST 15, 2023
More than a dozen startups have joined a few publicly traded biotechs and larger pharmaceutical firms in what’s become one of the most competitive areas in drug research.
BioPharma Drive: Drug Pricing
JULY 5, 2023
The deal enables Sarepta to quickly cash in on the clearance of Elevidys, with $102 million in new funds to help bankroll its drug research.
106 
BioPharma Drive: Drug Pricing
MARCH 12, 2024
Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
70 
BioPharma Drive: Drug Pricing
FEBRUARY 28, 2024
Well-known scientist and biotech entrepreneur Robert Langer is helping Lindus Health address longstanding challenges in contract drug research.
DrugBank
OCTOBER 30, 2024
At DrugBank, we’re dedicated to empowering pharmaceutical researchers with data that drives impactful results. Now, through our partnership with Snowflake, we’re making it even easier than ever for you to access high-quality, actionable data in a secure, and scalable environment designed to keep pace with your research needs.
75 
Cytel
JUNE 19, 2024
Historically, many drugs have been prescribed to children even though this patient population have largely been excluded from clinical trials. There is an obvious logic. If medicines are to be used in children, they need to be studied in pediatric populations to ensure they are safe and effective.
BioPharma Drive: Drug Pricing
JUNE 14, 2023
The alliance is Astellas’ second recent partnership involving protein degraders, an emerging area of drug research the company has made a focus in recent years.
67 
DrugBank
AUGUST 20, 2024
The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. The Power of Drug Repurposing Explore the immense potential of drug repurposing as a strategy for targeting undruggable targets.
72 
BioPharma Drive: Drug Pricing
JULY 6, 2023
The contract services provider, which secured the deal through a reportedly competitive process, expects CorEvitas to expand its drug research business.
BioPharma Drive: Drug Pricing
JULY 26, 2023
The startup, which initially aims to make cancer medicines, claims to have a new twist on covalent drug research.
52 
DrugBank
SEPTEMBER 12, 2024
At DrugBank we’re committed to improving your daily research and drug development operations. It’s designed to fit naturally into your existing processes, enhancing your ability to collaborate with standardized definitions and focus on your research tasks.
78 
Drug Channels
MARCH 5, 2024
The potential effect of the IRA on manufacturers’ new drug research and development strategies is beyond the scope of this webinar. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Pharmacies and Pharmacy Benefit Managers. Read on for full details on pricing and registration.
84 
Drug Target Review
OCTOBER 26, 2023
Alipogene tiparvovec and voretigene neparvovec-rzyl, two recombinant AAV-based gene therapy products, were approved by the European Medicines Agency (EMA) to treat lipoprotein lipase deficiency in 2012 2 and by the US Food and Drug Administration (FDA) to treat inherited retinal dystrophy in 2017, respectively.
105 
Drug Target Review
SEPTEMBER 21, 2023
Introduction I clearly remember an incident as a researcher, which kept happening, from my undergraduate research up till now. Summary of research The undergraduate study concentrated on the potential adulticidal effects of oral analgesics (acetaminophen, aspirin, and ibuprofen) on Onchocerca volvulus. doi: 10.1002/14651858.CD011146.pub2.
105 
DrugBank
MAY 15, 2024
The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess. Researchers would sift through natural extracts , hoping to stumble upon a compound that exhibited beneficial effects. In fact, it's one of the most exciting areas in drug research today.
Crown Bioscience
AUGUST 2, 2021
Continue reading to learn more about IMIDs and some of the challenges facing the field, and to review some in vivo preclinical models that can be used to guide IMID drug research and development.
52 
DrugBank
MARCH 22, 2024
There are many obstacles that you have to overcome on the road to success in early-stage drug discovery and drug repurposing research. As a result, the industry is turning to managed data sources and are having to weigh the costs and benefits of open data sources versus enterprise research tools.
74 
ACTO
SEPTEMBER 11, 2024
“The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. Current solutions are almost exclusively focused on marketing, HCP targeting, workflow automation, and performance insight.
52 
Advarra
AUGUST 16, 2022
Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. These centers, in conjunction with the FDA and U.S.
52 
Conversations in Drug Development Trends
FEBRUARY 21, 2024
As a result, we ensure collection of all urine and fecal samples over a period ranging between five to seven days, modifying the participant diet if needed.
The Pharma Data
APRIL 24, 2021
Novartis is advancing Research & Development of next-generation treatments to combat emerging drug resistance. As part of the PAMAfrica research consortium led by Medicines for Malaria Venture, we also initiated the development of a new formulation of our ACT for infants weighing less than 5 kilograms. Read the reports.
The Pharma Data
MAY 19, 2023
Yancopoulos Innovator Award , named in honor of the pioneering drug researcher and Regeneron co-founder, President and Chief Scientific Officer, for finding an efficient way to identify certain exoplanets that orbit very closely around their stars. Using her research, she says she found the smallest of these planets ever discovered.
52 
Codon
JANUARY 21, 2024
When a vaccine fails, that can have downstream effects on how other researchers in the field approach their own vaccine development, and how funding gets moved around. If a Shigella vaccine fails, researchers save a lot of money by not testing it in the field and having it fail there. But it's hard to find the counterfactual.
108 
Agency IQ
JUNE 7, 2024
FDA’s new guidance explains what to do during a BIMO inspection Under the FDA’s Bioresearch Monitoring (BIMO) program, the agency oversees the operation of regulated research. In short, the BIMO program oversees regulated research – both human and animal – in a variety of ways.
40 
NIH Director's Blog: Drug Development
FEBRUARY 16, 2021
These include drugs that you may have heard about on the news: remdesivir (an antiviral), dexamethasone (a steroid), and monoclonal antibodies from the companies Eli Lilly and Regeneron. Therapeutics Clinical Working Group : Prioritizes therapeutic agents for testing within an adaptive master protocol strategy for clinical research.
The Pharma Data
NOVEMBER 10, 2020
Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. Yong-Jun Liu , the newly appointed President of Innovent also made his first public appearance on the virtual R&D day.
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content